Substituted pyrimidodiazepines
The present invention provides PLK1 inhibitor compounds of formula I: Useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas.
1. A compound of formula I:
wherein
R2 is a member selected from the group consisting of cyclopentyl and cyclohexyl; and pharmaceutically acceptable salts thereof.
2. The compound of claim 1 wherein R2 is cyclopentyl.
3. The compound 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoic acid and pharmaceutically acceptable salts thereof.
4. The compound with the formula
5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
6. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable excipient.
7. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable excipient.